Also, overexpression of ARRDC3 confers breast cancer cell chemotherapy resistance [13], which were in parallel with our present result that upregulated ARRDC3 diminished the ESCC cell resistance to CIS and PT. The gene discussed is ARRDC3; the disease is in situ carcinoma.